0001209191-23-030661.txt : 20230518
0001209191-23-030661.hdr.sgml : 20230518
20230518164426
ACCESSION NUMBER: 0001209191-23-030661
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230516
FILED AS OF DATE: 20230518
DATE AS OF CHANGE: 20230518
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Nagendran Sukumar
CENTRAL INDEX KEY: 0001665124
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39536
FILM NUMBER: 23936752
MAIL ADDRESS:
STREET 1: C/O AVEXIS, INC., 2275 HALF DAY ROAD
STREET 2: SUITE 160
CITY: BANNOCKBURN
STATE: IL
ZIP: 60015
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Taysha Gene Therapies, Inc.
CENTRAL INDEX KEY: 0001806310
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 843199512
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3000 PEGASUS PARK DRIVE
STREET 2: SUITE 1430
CITY: DALLAS
STATE: TX
ZIP: 75247
BUSINESS PHONE: (214) 612-0000
MAIL ADDRESS:
STREET 1: 3000 PEGASUS PARK DRIVE
STREET 2: SUITE 1430
CITY: DALLAS
STATE: TX
ZIP: 75247
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-05-16
0
0001806310
Taysha Gene Therapies, Inc.
TSHA
0001665124
Nagendran Sukumar
C/O TAYSHA GENE THERAPIES, INC.
3000 PEGASUS PARK DRIVE, SUITE 1430
DALLAS
TX
75247
1
1
0
0
President and Head of R&D
0
Common Stock
2023-05-16
4
P
0
5000
0.68
A
34226
D
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.682 to $0.6879 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
/s/ Kamran Alam, Attorney-in-Fact
2023-05-18